Your browser doesn't support javascript.
loading
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
Wiechno, Pawel; Somer, Bradley G; Mellado, Begoña; Chlosta, Piotr L; Cervera Grau, José Manuel; Castellano, Daniel; Reuter, Christoph; Stöckle, Michael; Kamradt, Jörn; Pikiel, Joanna; Durán, Ignacio; Wedel, Steffen; Callies, Sophie; André, Valérie; Hurt, Karla; Brown, Jacqueline; Lahn, Michael; Heinrich, Bernhard.
Afiliação
  • Wiechno P; Uro-Oncology Department, Cancer Center, Warsaw, Poland. Electronic address: wiechno@coi.waw.pl.
  • Somer BG; West Clinic and ACORN, Memphis, TN, USA.
  • Mellado B; Medical Oncology Department, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Chlosta PL; Department of Urology, Jagiellonian University in Krakow, Krakow, Poland.
  • Cervera Grau JM; Benidorm Clinic Hospital, Benidorm, Spain.
  • Castellano D; Medical Oncology Service, 12 de Octubre University Hospital, Madrid, Spain.
  • Reuter C; Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Stöckle M; Clinic for Urology and Paediatric Urology, University of Saarland, Saarland, Germany.
  • Kamradt J; Clinic for Urology and Paediatric Urology, University of Saarland, Saarland, Germany.
  • Pikiel J; Wojewódzkie Cancer Centre, Gdansk, Poland.
  • Durán I; Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Wedel S; Department of Urology, Goethe-University, Frankfurt am Main, Germany.
  • Callies S; Global Pharmacokinetics/Pharmacodynamics Department, Eli Lilly and Company, Erl Wood, UK.
  • André V; Global Statistical Sciences, Eli Lilly and Company, Erl Wood, UK.
  • Hurt K; Division of Early Phase Oncology Clinical Investigation, Eli Lilly and Company, Indianapolis, IN, USA.
  • Brown J; Global Health Outcomes, Eli Lilly and Company, Erl Wood, UK.
  • Lahn M; Division of Early Phase Oncology Clinical Investigation, Eli Lilly and Company, Indianapolis, IN, USA.
  • Heinrich B; Haematological-Oncological Practice Brudler/Heinrich/Bangerter, Augsburg, Germany.
Eur Urol ; 65(3): 516-20, 2014 Mar.
Article em En | MEDLINE | ID: mdl-24246407
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Prednisona / Taxoides / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Prednisona / Taxoides / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article